Sex differences in long-term safety and tolerability of Growth Hormone (GH) Replacement Therapy in GH deficient adults.

Data obtained from the Dutch National Registry of GH Treatment in Adults indicate that GHD women might be treated suboptimal, reflected as lower IGF-1 status and are less tolerable of GHRT, which more often led to changes in treatment regime but not discontinuation of GHRT. Regarding long-term safety, we found a higher risk in development of malignancies in GHD men.